8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Dec 22, 2025·SEC
Fulgent Genetics, Inc.(FLGT)Earnings, Financials & Key Ratios
FLGT•NASDAQ
Price updated Jun 19, 2026
AboutFulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.Show more
- Revenue$323M+13.8%
- EBITDA-$67M-36.7%
- Net Income-$61M-41.7%
- EPS (Diluted)-1.97-39.7%
- Gross Margin40.56%+7.2%
- EBITDA Margin-20.76%-20.1%
- Operating Margin-28.23%-8.3%
- Net Margin-18.75%-24.5%
- ROE-5.41%-43.4%
FLGT Key Insights
Fulgent Genetics, Inc. (FLGT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 5.2% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FLGT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FLGT Price & Volume
Fulgent Genetics, Inc. (FLGT) stock price & volume — 10-year historical chart
Loading chart...
FLGT Growth Metrics
Fulgent Genetics, Inc. (FLGT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years42.15%
5 Years-5.21%
3 Years-19.52%
TTM13.83%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-41.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.3%
Return on Capital
10 Years13.67%
5 Years12.33%
3 Years-10.1%
Last Year-8.01%
FLGT Recent Earnings
Fulgent Genetics, Inc. (FLGT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$0.36-3.4%
$0.35
Rev
$71M+4.5%
$68M
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.16+433.3%
$0.03
Rev
$83M-2.4%
$85M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.14+158.3%
$0.24
Rev
$84M-1.5%
$85M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.07+130.4%
$0.23
Rev
$82M+0.5%
$81M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.36vs $0.35-3.4% | $71Mvs $68M+4.5% |
| Q1 2026 | Feb 27, 2026 | $0.16vs $0.03+433.3% | $83Mvs $85M-2.4% |
| Q4 2025 | Nov 7, 2025 | $0.14vs $0.24+158.3% | $84Mvs $85M-1.5% |
| Q3 2025 | Aug 1, 2025 | $0.07vs $0.23+130.4% | $82Mvs $81M+0.5% |
Based on last 12 quarters of dataView full earnings history →
FLGT Peer Comparison
Fulgent Genetics, Inc. (FLGT) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 LH | 21.05B | 255.82 | 24.46 | 7.25% | 6.66% | 10.89% | 0.83 | |
 DGX | 21.58B | 195.00 | 22.29 | 11.78% | 9.08% | 13.8% | 0.95 | |
 MYRG | 7.18B | 461.10 | 61.24 | 8.79% | 3.71% | 22.14% | 0.16 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 PGNY | 2.04B | 26.08 | 40.12 | 10.4% | 5.23% | 13.34% | 0.05 |
Compare FLGT vs Peers
Fulgent Genetics, Inc. (FLGT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FLGT Income Statement
Fulgent Genetics, Inc. (FLGT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 18.73M | 21.36M | 32.53M | 421.71M | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
Revenue Growth % | 2.48% | 14.03% | 52.31% | 1196.46% | 135.37% | -37.64% | -53.27% | -1.99% | 13.83% |
Cost of Goods Sold | 8.55M | 10.69M | 14.11M | 89.81M | 215.53M | 252.07M | 184.76M | 176.25M | 191.8M |
COGS % of Revenue | 45.65% | 50.06% | 43.37% | 21.3% | 21.71% | 40.72% | 63.88% | 62.18% | 59.44% |
Gross Profit | 10.18M▲ 0% | 10.66M▲ 4.8% | 18.42M▲ 72.7% | 331.9M▲ 1701.8% | 777.05M▲ 134.1% | 366.9M▼ 52.8% | 104.46M▼ 71.5% | 107.22M▲ 2.6% | 130.88M▲ 22.1% |
Gross Margin % | 54.35% | 49.94% | 56.63% | 78.7% | 78.29% | 59.28% | 36.12% | 37.82% | 40.56% |
Gross Profit Growth % | -11.91% | 4.77% | 72.72% | 1701.78% | 134.12% | -52.78% | -71.53% | 2.64% | 22.07% |
Operating Expenses | 13.58M | 15.72M | 18.85M | 41.75M | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
OpEx % of Revenue | 72.5% | 73.62% | 57.95% | 9.9% | 10.19% | 30.43% | 103.72% | 63.9% | 68.79% |
Selling, General & Admin | 9.44M | 10.19M | 12.31M | 30.17M | 75.17M | 149.99M | 130.47M | 124.35M | 160.03M |
SG&A % of Revenue | 50.39% | 47.7% | 37.85% | 7.15% | 7.57% | 24.23% | 45.11% | 43.87% | 49.6% |
Research & Development | 4.22M | 5.53M | 6.54M | 11.58M | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
R&D % of Revenue | 22.55% | 25.91% | 20.1% | 2.75% | 2.44% | 4.67% | 14.33% | 17.22% | 16.71% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 1.71M | 9.47M | 128.08M | 7.96M | 8.03M |
Operating Income | -3.48M▲ 0% | -5.07M▼ 45.6% | -428K▲ 91.6% | 290.16M▲ 67893.9% | 675.95M▲ 133.0% | 178.53M▼ 73.6% | -195.53M▼ 209.5% | -73.92M▲ 62.2% | -91.1M▼ 23.2% |
Operating Margin % | -18.59% | -23.74% | -1.32% | 68.8% | 68.1% | 28.84% | -67.61% | -26.08% | -28.23% |
Operating Income Growth % | -478.89% | -45.61% | 91.56% | 67893.93% | 132.96% | -73.59% | -209.52% | 62.2% | -23.24% |
EBITDA | -1.75M | -2.91M | 1.68M | 293.12M | 686.96M | 211.19M | -169.39M | -48.99M | -66.97M |
EBITDA Margin % | -9.36% | -13.61% | 5.16% | 69.51% | 69.21% | 34.12% | -58.57% | -17.28% | -20.76% |
EBITDA Growth % | -183.96% | -65.74% | 157.76% | 17358.01% | 134.36% | -69.26% | -180.21% | 71.08% | -36.71% |
D&A (Non-Cash Add-back) | 1.73M | 2.16M | 2.11M | 2.96M | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
EBIT | -3.48M | -5.07M | -428K | 290.16M | 675.95M | 185.04M | -173.6M | -73.92M | -69.95M |
Net Interest Income | 481K | 434K | 837K | 1.53M | 1.35M | 4.61M | 21.12M | 31.13M | 30.84M |
Interest Income | 481K | 434K | 837K | 1.53M | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 1.01M | 488K | 170K | 75K |
Other Income/Expense | 481K | 434K | 60K | -3.32M | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
Pretax Income | -3M▲ 0% | -4.64M▼ 54.5% | -368K▲ 92.1% | 286.84M▲ 78046.2% | 681.03M▲ 137.4% | 184.03M▼ 73.0% | -174.09M▼ 194.6% | -51.96M▲ 70.2% | -70.03M▼ 34.8% |
Pretax Margin % | -16.02% | -21.71% | -1.13% | 68.02% | 68.61% | 29.73% | -60.19% | -18.33% | -21.7% |
Income Tax | -1.01M | 36K | 43K | 72.53M | 174.79M | 42.1M | 1.15M | -8.14M | -8.39M |
Effective Tax Rate % | 33.82% | -0.78% | -11.68% | 25.29% | 25.67% | 22.88% | -0.66% | 15.66% | 11.99% |
Net Income | -2.51M▲ 0% | -5.61M▼ 123.4% | -411K▲ 92.7% | 214.31M▲ 52243.6% | 507.36M▲ 136.7% | 143.4M▼ 71.7% | -167.82M▼ 217.0% | -42.71M▲ 74.6% | -60.51M▼ 41.7% |
Net Margin % | -13.4% | -26.25% | -1.26% | 50.82% | 51.12% | 23.17% | -58.03% | -15.07% | -18.75% |
Net Income Growth % | 53.06% | -123.39% | 92.67% | 52243.55% | 136.74% | -71.74% | -217.03% | 74.55% | -41.69% |
Net Income (Continuing) | -1.99M | -5.61M | -411K | 214.31M | 506.24M | 141.92M | -175.24M | -43.82M | -61.63M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 7.13M | 3.19M | -2.81M | -4.07M | -5.27M |
EPS (Diluted) | -0.15▲ 0% | -0.25▼ 66.7% | -0.02▲ 92.0% | 8.91▲ 44650.0% | 16.26▲ 82.5% | 4.63▼ 71.5% | -5.63▼ 221.6% | -1.41▲ 75.0% | -1.97▼ 39.7% |
EPS Growth % | 50% | -66.67% | 92% | 44650% | 82.49% | -71.53% | -221.6% | 74.96% | -39.72% |
EPS (Basic) | -0.15 | -0.25 | -0.02 | 9.44 | 17.13 | 4.76 | -5.63 | -1.41 | -1.97 |
Diluted Shares Outstanding | 17.74M | 17.98M | 18.71M | 24.06M | 30.98M | 30.96M | 29.78M | 30.23M | 30.78M |
Basic Shares Outstanding | 17.74M | 17.98M | 18.71M | 22.69M | 29.41M | 30.1M | 29.78M | 30.23M | 30.78M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
FLGT Balance Sheet
Fulgent Genetics, Inc. (FLGT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 45.37M | 43.37M | 37.08M | 523.62M | 611.96M | 627.87M | 507.85M | 353.57M | 550.49M |
Cash & Short-Term Investments | 41.37M | 37.42M | 28.27M | 299.37M | 450.5M | 526.24M | 424.15M | 258.11M | 336.08M |
Cash Only | 6.49M | 6.74M | 11.96M | 87.43M | 164.89M | 79.51M | 97.47M | 55.14M | 50.19M |
Short-Term Investments | 34.88M | 30.68M | 16.3M | 211.94M | 285.61M | 446.73M | 326.68M | 202.96M | 285.88M |
Accounts Receivable | 4.07M | 6.24M | 7.2M | 204.06M | 143.29M | 75.11M | 57.45M | 77.03M | 84.76M |
Days Sales Outstanding | 79.33 | 106.61 | 80.78 | 176.62 | 52.69 | 44.29 | 72.5 | 99.18 | 95.88 |
Inventory | 231K | 314K | 277K | 16.49M | 12.21M | 4.28M | 0 | 8.38M | 0 |
Days Inventory Outstanding | 9.86 | 10.72 | 7.17 | 67.02 | 20.67 | 6.2 | - | 17.36 | - |
Other Current Assets | 231K | 0 | 0 | 0 | 0 | 0 | 5.83M | 0 | 129.65M |
Total Non-Current Assets | 11.58M | 11.64M | 51.68M | 176.84M | 666.76M | 758.18M | 727.48M | 866.39M | 663.03M |
Property, Plant & Equipment | 7.27M | 6.45M | 8.61M | 40.2M | 62.29M | 81.35M | 95.62M | 105.55M | 112.55M |
Fixed Asset Turnover | 2.58x | 3.31x | 3.78x | 10.49x | 15.94x | 7.61x | 3.02x | 2.69x | 2.87x |
Goodwill | 0 | 0 | 0 | 0 | 50.9M | 143.03M | 22.05M | 22.05M | 25.08M |
Intangible Assets | 0 | 0 | 0 | 0 | 35.91M | 150.64M | 143.05M | 134.98M | 64.79M |
Long-Term Investments | 16.82M | 7.9M | 42.82M | 132.5M | 507.01M | 339.03M | 444.01M | 570.35M | 0 |
Other Non-Current Assets | 4.31M | -2.7M | 251K | 4.14M | 10.65M | 44.12M | 22.75M | 33.46M | 460.62M |
Total Assets | 56.95M▲ 0% | 55.02M▼ 3.4% | 88.76M▲ 61.3% | 700.46M▲ 689.2% | 1.28B▲ 82.6% | 1.39B▲ 8.4% | 1.24B▼ 10.9% | 1.22B▼ 1.2% | 1.21B▼ 0.5% |
Asset Turnover | 0.33x | 0.39x | 0.37x | 0.60x | 0.78x | 0.45x | 0.23x | 0.23x | 0.27x |
Asset Growth % | -1.88% | -3.4% | 61.33% | 689.2% | 82.55% | 8.39% | -10.87% | -1.24% | -0.53% |
Total Current Liabilities | 2.92M | 2.75M | 3.72M | 130.12M | 105.31M | 88.11M | 73.02M | 72.9M | 84.97M |
Accounts Payable | 2.09M | 1.31M | 1.58M | 26.49M | 20.49M | 23.09M | 15.36M | 18.36M | 18.65M |
Days Payables Outstanding | 89.17 | 44.82 | 40.91 | 107.65 | 34.71 | 33.44 | 30.34 | 38.03 | 35.5 |
Short-Term Debt | 0 | 0 | 0 | 15.02M | 21.28M | 20.64M | 1.18M | 412K | 476K |
Deferred Revenue (Current) | 0 | 0 | 365K | 26.76M | 34.38M | 14.09M | 25.57M | 29.84M | 28.14M |
Other Current Liabilities | 0 | 166K | 0 | -185K | 10.68M | 5.3M | 164K | 5.8M | 37.69M |
Current Ratio | 15.51x | 15.80x | 9.96x | 4.02x | 5.81x | 7.13x | 6.96x | 4.85x | 6.48x |
Quick Ratio | 15.43x | 15.69x | 9.89x | 3.90x | 5.70x | 7.08x | 6.96x | 4.74x | 6.48x |
Cash Conversion Cycle | 0.02 | 72.51 | 47.04 | 135.99 | 38.66 | 17.05 | - | 78.52 | - |
Total Non-Current Liabilities | 6K | 14K | 2.26M | 959K | 7.53M | 28.07M | 29.02M | 17.91M | 21.84M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 3.37M | 2.96M | 2.49M | 0 |
Capital Lease Obligations | 0 | 0 | 2.26M | 568K | 0 | 8.79M | 7.15M | 4.12M | 0 |
Deferred Tax Liabilities | 820K | 718K | 0 | 0 | 0 | 0 | 7.96M | 6.37M | 6.94M |
Other Non-Current Liabilities | 6K | 14K | 0 | 391K | 7.53M | 15.9M | 10.95M | 4.92M | 14.91M |
Total Liabilities | 2.92M | 2.75M | 5.98M | 131.07M | 112.84M | 116.18M | 102.04M | 90.81M | 106.81M |
Total Debt | 0 | 0 | 2.68M | 15.85M | 21.28M | 38.94M | 15.25M | 8.47M | 476K |
Net Debt | -6.49M | -6.74M | -9.29M | -71.57M | -143.61M | -40.57M | -82.22M | -46.68M | -49.72M |
Debt / Equity | - | - | 0.03x | 0.03x | 0.02x | 0.03x | 0.01x | 0.01x | 0.00x |
Debt / EBITDA | - | - | 1.59x | 0.05x | 0.03x | 0.18x | - | - | - |
Net Debt / EBITDA | - | - | -5.53x | -0.24x | -0.21x | -0.19x | - | - | - |
Interest Coverage | - | - | - | - | - | 182.66x | -355.73x | -434.81x | -932.67x |
Total Equity | 54.03M▲ 0% | 52.27M▼ 3.3% | 82.78M▲ 58.4% | 569.39M▲ 587.9% | 1.17B▲ 104.8% | 1.27B▲ 8.9% | 1.13B▼ 10.8% | 1.13B▼ 0.4% | 1.11B▼ 2.0% |
Equity Growth % | -0.83% | -3.25% | 58.36% | 587.86% | 104.76% | 8.92% | -10.76% | -0.36% | -1.99% |
Book Value per Share | 3.05 | 2.91 | 4.42 | 23.67 | 37.64 | 41.01 | 38.05 | 37.35 | 35.96 |
Total Shareholders' Equity | 54.03M | 52.27M | 82.78M | 569.39M | 1.16B | 1.27B | 1.14B | 1.13B | 1.11B |
Common Stock | 2K | 2K | 2K | 3K | 3K | 3K | 3K | 3K | 3K |
Retained Earnings | -57.66M | -63.02M | -63.43M | 150.88M | 657.6M | 801M | 633.17M | 590.47M | 529.95M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -44K | -35K | 146K | 438K | -759K | -20.9M | 1.21M | -368K | 7.51M |
Minority Interest | 0 | 0 | 0 | 0 | 7.13M | 3.19M | -2.81M | -4.07M | -5.27M |
FLGT Cash Flow Statement
Fulgent Genetics, Inc. (FLGT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.33M | -675K | 5.52M | 140.63M | 538.58M | 253.52M | 27M | 21.06M | -101.64M |
Operating CF Margin % | 7.11% | -3.16% | 16.96% | 33.35% | 54.26% | 40.96% | 9.34% | 7.43% | -31.5% |
Operating CF Growth % | -69.78% | -150.71% | 917.33% | 2448.99% | 282.98% | -52.93% | -89.35% | -22.01% | -582.61% |
Net Income | -2.51M | -5.61M | -411K | 214.31M | 506.24M | 141.92M | -175.24M | -43.82M | -61.63M |
Depreciation & Amortization | 1.73M | 2.16M | 2.52M | 2.96M | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
Stock-Based Compensation | 2.12M | 2.3M | 0 | 8.16M | 15.88M | 32.64M | 42.92M | 44.48M | 39.58M |
Deferred Taxes | -336K | 36K | -21K | -1.4M | -7.84M | 831K | 7.61M | -5.15M | -1.21M |
Other Non-Cash Items | 1.04M | 1.67M | 4.34M | 8.05M | 15.97M | 43.46M | 122.73M | 7.86M | 15.14M |
Working Capital Changes | -714K | -1.24M | -915K | -91.45M | -2.68M | 2M | 2.84M | -7.24M | -117.63M |
Change in Receivables | 214K | -1.97M | -839K | -178.48M | 42.3M | 68.64M | 2.39M | -16.3M | -23.25M |
Change in Inventory | -30.49M | -36.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -363K | 102K | -329K | 22.62M | -12.21M | -25.34M | -6.9M | 3.07M | 550K |
Cash from Investing | -2.05M | 950K | -29.05M | -326.44M | -546.55M | -261.31M | 38.9M | -58.35M | 111.37M |
Capital Expenditures | -5.36M | -2.83M | -1.18M | -36.51M | -23.81M | -18.77M | -22.21M | -40.31M | -22.57M |
CapEx % of Revenue | 28.6% | 13.26% | 3.63% | 8.66% | 2.4% | 3.03% | 7.68% | 14.22% | 7% |
Acquisitions | 2.46M | 510K | 0 | -2.59M | -61.87M | -182.68M | -399K | 0 | 3.77M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -2.46M | -510K | 0 | 8K | 31K | 412K | 775K | 313K | 5K |
Cash from Financing | -770K | 15K | 28.77M | 261.25M | 85.41M | -77.14M | -47.78M | -4.85M | -14.79M |
Debt Issued (Net) | 0 | 0 | 0 | 15.02M | -11K | -1.07M | -20M | -1.77M | -870K |
Equity Issued (Net) | 0 | 0 | 28.77M | 246.13M | 85.32M | -76.11M | -27.79M | -3.12M | -10.88M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -21K | -62K | -4.16M | -76.11M | -27.79M | -3.12M | -10.88M |
Other Financing | -770K | 15K | 0 | 104K | 96K | 31K | 3K | 51K | -3.04M |
Net Change in Cash | -1.41M▲ 0% | 246K▲ 117.5% | 5.23M▲ 2025.6% | 75.46M▲ 1343.1% | 77.47M▲ 2.7% | -85.39M▼ 210.2% | 17.97M▲ 121.0% | -42.19M▼ 334.8% | -4.95M▲ 88.3% |
Free Cash Flow | -4.03M▲ 0% | -3.51M▲ 12.9% | 4.33M▲ 223.6% | 104.12M▲ 2301.8% | 514.73M▲ 394.4% | 234.75M▼ 54.4% | 4.8M▼ 98.0% | -19.25M▼ 501.5% | -124.21M▼ 545.1% |
FCF Margin % | -21.49% | -16.42% | 13.33% | 24.69% | 51.86% | 37.93% | 1.66% | -6.79% | -38.49% |
FCF Growth % | -752.35% | 12.87% | 223.61% | 2301.8% | 394.37% | -54.39% | -97.96% | -501.48% | -545.09% |
FCF per Share | -0.23 | -0.20 | 0.23 | 4.33 | 16.62 | 7.58 | 0.16 | -0.64 | -4.04 |
FCF Conversion (FCF/Net Income) | -0.53x | 0.12x | -13.42x | 0.66x | 1.06x | 1.77x | -0.16x | -0.49x | 1.68x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 960K | 512K | 0 |
Taxes Paid | 757K | 1K | 0 | 20.61M | 237.07M | 56.19M | 3.26M | 27.59M | 0 |
FLGT Key Ratios
Fulgent Genetics, Inc. (FLGT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -17.94% | -4.63% | -10.55% | -0.61% | 65.72% | 58.48% | 11.77% | -13.97% | -3.78% | -5.41% |
Return on Invested Capital (ROIC) | 2.69% | -5.55% | -8.17% | -0.54% | 76.18% | 66.7% | 11.89% | -12.86% | -5.2% | -6.39% |
Gross Margin | 63.22% | 54.35% | 49.94% | 56.63% | 78.7% | 78.29% | 59.28% | 36.12% | 37.82% | 40.56% |
Net Margin | -29.26% | -13.4% | -26.25% | -1.26% | 50.82% | 51.12% | 23.17% | -58.03% | -15.07% | -18.75% |
Debt / Equity | - | - | - | 0.03x | 0.03x | 0.02x | 0.03x | 0.01x | 0.01x | 0.00x |
Interest Coverage | 0.17x | - | - | - | - | - | 182.66x | -355.73x | -434.81x | -932.67x |
FCF Conversion | -0.82x | -0.53x | 0.12x | -13.42x | 0.66x | 1.06x | 1.77x | -0.16x | -0.49x | 1.68x |
Revenue Growth | 90.85% | 2.48% | 14.03% | 52.31% | 1196.46% | 135.37% | -37.64% | -53.27% | -1.99% | 13.83% |
Related:FLGT Dividend History·FLGT Revenue History·FLGT Price History·FLGT P/E History·FLGT Financial Ratios·FLGT Institutional Holders
FLGT SEC Filings & Documents
Fulgent Genetics, Inc. (FLGT) SEC filings — annual & quarterly reports (10-K, 10-Q)
FLGT Frequently Asked Questions
Fulgent Genetics, Inc. (FLGT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fulgent Genetics, Inc. (FLGT) reported $322.7M in revenue for fiscal year 2025. This represents a 25148% increase from $1.3M in 2014.
Fulgent Genetics, Inc. (FLGT) grew revenue by 13.8% over the past year. This is steady growth.
Fulgent Genetics, Inc. (FLGT) reported a net loss of $60.5M for fiscal year 2025.
Dividend & Returns
Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.
Fulgent Genetics, Inc. (FLGT) had negative free cash flow of $124.2M in fiscal year 2025, likely due to heavy capital investments.